

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A diacylhydrazine compound ~~Diacylhydrazine~~
~~derivatives of formula I:~~



(I)

wherein

D is a bivalent diacylhydrazine moiety, or a derivative thereof; ~~[[.]]~~

A is an ~~an~~ ~~[[a]]~~ unsubstituted or substituted moiety of up to 40 carbon atoms
of the formula: $-L-(M-L')_{\alpha}$, where

L is a 5, 6 or 7 membered cyclic structure ~~[[.]]~~ selected from ~~the~~
~~group consisting of~~ aryl, heteroaryl, arylene and heteroarylene, bound
directly to D,

L' comprises an optionally substituted cyclic moiety having at
least 5 members, selected from the group consisting of aryl, heteroaryl,
aralkyl, cycloalkyl and heterocyclyl,

M is a bond or a bridging group having at least one atom, α
is an integer of from 1-4, ~~[[.]]~~ and

each cyclic structure of L and L' contains 0-4 members of the
group consisting of nitrogen, oxygen and sulfur,

wherein L' is substituted by at least one substituent selected
from ~~the group consisting of~~ $-\text{SO}_2\text{R}_x$, $-\text{C}(\text{O})\text{R}_x$ and $-\text{C}(\text{NR}_y)\text{R}_z$; ~~[[.]]~~

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety
of up to 30 carbon ~~carbon~~ atoms, comprising at least one 5-, 6-, or 7-
membered cyclic structure, bound directly to D containing 0-4 members
of the group consisting of nitrogen, oxygen and sulfur, wherein said

cyclic structure directly bound to D is selected from the group consisting of aryl, heteroaryl and heterocyclyl; [I.]

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O, and optionally halosubstituted, up to per halo; [I.]

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_e or NR_aR_b, where R_a and R_b are

- a) independently hydrogen, a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

or

- b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from ~~the group consisting of~~ halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L' is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_γ , where γ is 0-3;

~~wherein each~~

W is independently selected from ~~the group consisting of~~ $-CN$, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$, $-Q-Ar$, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the groups consisting of $-CN$, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$ and halogen up to per-halo; ~~with each~~

R^5 independently is selected from H or a carbon based moiety of up to 24

carbon atoms, optionally containing heteroatoms selected from N, S and O, and optionally substituted by halogen, wherein Q is -O-, -S-, -N(R⁵)-, -(CH₂)_β-, -C(O)-, -CH(OH)-, -(CH₂)_β-, -(CH₂)_βS-, -(CH₂)_βN(R⁵)-, -O(CH₂)_β-CHHal-, -CHAl₂-, -S-(CH₂)- and -N(R⁵)(CH₂)_β-; where

$$\beta = 1-3; \text{ and}$$

Hal is halogen; and

Ar is 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{δ1} wherein δ1 is 0 to 3 and each Z is independently selected from the group consisting -CN, -CO₂R⁵, -C(O)NR⁵R⁵, -C(O)-R⁵, -NO₂, -OR⁵, -SR⁵, -SO₂R⁵, -SO₃H, -NR⁵R⁵, -NR⁵C(O)OR⁵, -NR⁵C(O)R⁵, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁵, -C(O)NR⁵R⁵, -C(O)-R⁵, -NO₂, -OR⁵, -SR⁵, -SO₂R⁵, -SO₃H, -NR⁵R⁵, -NR⁵C(O)OR⁵, -NR⁵C(O)R⁵, and the or a pharmaceutically acceptable derivative, salt, or solvate derivatives, salts and solvates thereof.

2. (Currently Amended): A diacylhydrazine compound Diacylhydrazine derivative according to claim 1, wherein characterised in that

each M independently from one another represents a bond or is a bridging group, selected from the group consisting of (CR⁵R⁵)_n or (CHR⁵)_n-Q-(CHR⁵)_n, wherein

Q is selected from a group consisting of O, S, N-R⁵, CH¹⁵H¹⁶, (CHAl₂)_n, (O-CHR⁵)_n, (CHR⁵-O)_n, CR⁵=CR⁵, (O-CHR⁵CHR⁵)_n, (CHR⁵CHR⁵-O)_n, C=O, C=S, C=NR⁵, CH(OR⁵), C(OR⁵)(OR⁵), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R⁵)C(=O), OC(=O)N(R⁵),


$N(R^5)C(=O)O$, $CH=N-NR^5$, $OC(O)NR^5$, $NR^5C(O)O$, $S=O$, SO_2 , SO_2NR^5 and NR^5SO_2 ,
wherein

R^5 — is in each case independently selected from the meanings given above,
preferably hydrogen, halogen, alkyl, aryl, aralkyl,

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, and

j is 1, 2, 3, 4, 5 or 6.

3. (Currently Amended): A diacylhydrazine compound ~~Diacylhydrazine~~
~~derivative~~ according to claim 1, selected from the compounds of formula II,



wherein

Ar^1 , Ar^2 are each selected ~~independently selected~~ ~~from one another from~~ aromatic
hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or
aromatic heterocyclic residues containing 3 to 10 carbon atoms and one, two,
~~we~~ or three hetero atoms, independently selected from N, O and ~~and~~ S,

E, G, M, Q and U are each selected, ~~independently selected~~ ~~from one another, from~~
carbon atoms and nitrogen atoms, with the proviso that one or more of E, G,
M, Q and U are carbon atoms and that X is bonded to a carbon atom,

R^8 , R^9 and R^{10} are each independently selected from ~~a group consisting of~~ H, A, OA,
cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$,

NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{OR}^{11}$, $(\text{CH}_2)_n\text{NR}^{11}(\text{CH}_2)_k\text{OR}^{12}$,
 $(\text{CH}_2)_n\text{COOR}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$,
 $(\text{CH}_2)_n\text{NR}^8\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{S}(\text{O})_v\text{R}^{13}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, $\text{CH}=\text{N}-\text{OA}$,
 $\text{CH}_2\text{CH}=\text{N}-\text{OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N}-\text{R}^{11}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{11}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$,
 $\text{CH}=\text{CHCOOR}^{13}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$,
 $\text{CH}=\text{CHCH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{COOR}^{13})\text{COOR}^{14}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{13}$,
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$,
 $(\text{CH}_2)_n\text{OCN}$ and $(\text{CH}_2)_n\text{NCO}$, **wherein**

R^{11} , R^{12} are each independently selected from **a group consisting of** H, A, $(\text{CH}_2)_m\text{Ar}^3$
 and $(\text{CH}_2)_m\text{Het}$, or

in $\text{NR}^{11}\text{R}^{12}$, R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or
 7- membered heterocyclyl ~~heterocycle~~ which optionally contains 1 or 2
 additional hetero atoms, selected from N, O and S,

R^{13} , R^{14} are each independently selected from **a group consisting of** H, Hal, A,
 $(\text{CH}_2)_m\text{Ar}^4$ and $(\text{CH}_2)_m\text{Het}$,

A is selected from the **group consisting of** alkyl, alkenyl, cycloalkyl,
 alkylidenecycloalkyl, alkoxy, alkoxyalkyl and saturated heterocyclyl,

Ar^3 , Ar^4 are each independently from one another aromatic hydrocarbon residues
 comprising 5 to 12 carbon atoms which are optionally substituted by one or

more substituents, selected from ~~a group consisting of~~ A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_nA and OOCR¹⁵,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from ~~a group consisting of~~ A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_nA and OOCR¹⁵,

R¹⁵, R¹⁶ are independently selected from ~~a group consisting of~~ H, A, and (CH₂)_mAr⁶, wherein

Ar⁶ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from ~~a group consisting of~~ methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is (CR¹¹R¹²)_h, or (CHR¹¹)_h-Q-(CHR¹²)_h, wherein

Q is selected from ~~a group consisting of~~ T, CH¹⁵H¹⁶, (CHal₂)_j, (O-CHR¹⁸)_j, (CHR¹⁸-O)_j, CR¹⁸=CR¹⁹, (O-CHR¹⁸CHR¹⁹)_j, CHR¹⁸CHR¹⁹-O)_j, C=O, C=S, C=NR¹⁵, CH(OR¹⁵), C(OR¹⁵)(OR²⁰), C(=O)O, OC(=O), OC(=O)O, C(=N(R¹⁵), N(R¹⁵)C(=O), OC(=O)N(R¹⁵), N(R¹⁵)C(=O)O, CH=N-O, CH=N-NR¹⁵, OC(O)NR¹⁵, NR¹⁵C(O)O, S=O, SO₂, SO₂NR¹⁵ and ~~and~~ NR¹⁵SO₂, wherein

T is selected from O, S, N-R¹⁵,

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, ~~and~~

j is 1, 2, 3, 4, 5 or 6,

Y is selected from O/S, NR²¹, C(R²²)-NO₂, C(R²²)-CN and C(CN)₂, wherein

O/S is ~~selected from O or~~ [.,] S,

R²¹ is independently selected from H, Hal, A, (CH₂)_mAr⁴ and (CH₂)_mHet, ~~the meanings given for R¹², R¹⁴, and~~

R²² is independently selected from H, A, (CH₂)_mAr³ and (CH₂)_mHet, ~~the meanings given for R¹⁴, R¹³,~~

p, r are independently from one another 0, 1, 2, 3, 4 or 5,


q is 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3, and


Hal is independently selected from ~~a group consisting of~~ F, Cl, Br and I,

and the pharmaceutically acceptable derivatives, salts and solvates thereof.

4. (Currently Amended): A diacylhydrazine compound ~~Diacylhydrazine derivative~~ according to claim 3, selected from the compounds of formula IIa, IIb, IIc, IId, IIe, IIg, IIh, Iii, IIj, IIk, IIl, IIm, IIn, IIo, IIp, IIq, IIr, IIu, IIv, IIw and IIx,




IIb




IIb


IIc




IIc








IId













IId






IIf









wherein R^6 , R^7 , R^8 , p , Ar^1 , Y , X , R^9 and q are as defined in claim 3, R^{10} is H or as defined in claim 3; and the pharmaceutically acceptable derivatives, salts and solvates thereof.

5. (Currently Amended): A diacylhydrazine compound ~~Diacylhydrazine~~ selected from the compounds of formula II as defined in according to claim 3, wherein

E, G, M, U and Q are each carbon atoms,

X is O or a bond,

Y is O,

Ar¹ is phenyl or indolyl,

Ar² is pyridinyl,

R⁸ is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

R¹⁰ is H or CONCH₃,

p is 0, 1, 2 or 3,

q is 0₂ and

r is 1

~~and the pharmaceutically acceptable derivatives, salts and solvates thereof.~~

6. (Currently Amended): A diacylhydrazine compound ~~Diaacylhydrazine derivative~~ according to claim 5, wherein X is O and R¹⁰ is CONCH₃ ~~and the pharmaceutically acceptable derivatives, salts and solvates thereof.~~

7. (Currently Amended): A diacylhydrazine compound ~~Diaacylhydrazine derivative~~ according to claim 5, wherein X is a bond and R¹⁰ is H ~~and the pharmaceutically acceptable derivatives, salts and solvates thereof.~~

8. (Currently Amended): A diacylhydrazine compound ~~Diaacylhydrazine derivative selected from the compounds of formula II as defined in~~ according to claim 3, wherein E, G, M, U and Q are each carbon atoms, X is O, S or NR¹⁵₁ and Y is O ~~and the pharmaceutically acceptable derivatives, salts and solvates thereof.~~

9. (Currently Amended): A diacylhydrazine compound ~~Diaeylhydrazine~~ derivative according to claim 1, selected from the compounds (1) to (224) of table 1 and the compounds (225) to (384) of table 2, and the pharmaceutically acceptable derivatives, salts and solvates thereof.

10. (Currently Amended): A medicament comprising a diacylhydrazine compound ~~Diaeylhydrazine derivative~~ according to claim 1 as a medicament.

11. (Currently Amended): A method of treating a patient suffering from a disease mediated by the raf kinase pathway, comprising administering to said patient an effective amount of a kinase inhibitor, wherein said kinase inhibitor is a compound ~~Diaeylhydrazine derivative~~ according to claim 1 ~~as a kinase inhibitor~~.

12. (Currently Amended): A method according to claim 11, wherein said kinase inhibitor is a raf-kinase inhibitor ~~Diaeylhydrazine derivative~~ according to claim 11, characterized in that the kinases are selected from raf-kinases.

13. (Currently Amended): A pharmaceutical ~~Pharmaceutical~~ composition comprising ~~characterised in that it contains~~ one or more compounds according to claim 1 and one or more additional compounds.

14. (Currently Amended): A pharmaceutical ~~Pharmaceutical~~ composition according to claim 13, ~~characterised in that it contains~~ wherein said one or more additional compounds ~~[[.]] are selected from the group consisting of~~ physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.

15. (Withdrawn; Currently Amended): A process ~~Proecess~~ for the manufacture of a pharmaceutical composition, comprising processing by mechanical means ~~characterised in that~~ one or more compounds according to claim 1 and one or more compounds ~~[[.]] selected from the group consisting of~~ carriers, excipients, auxiliaries and pharmaceutical active ingredients, other than the compounds according to claim 1, is processed by mechanical

means into a pharmaceutical composition that is suitable as dosage form ~~dosage form~~ for application and/or administration to a patient.

16. (Cancelled):

17. (Cancelled):

18. (Cancelled):

19. (Currently Amended): A method for the treatment or prophylaxis of a disorder ~~Use according to claim 17, characterised in that the disorders are~~ caused, mediated and/or propagated by raf-kinases, said method comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

20. (Currently Amended): A method ~~Use according to claim 19 47, characterised in that the disorders are~~ wherein said disorder is selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.

21. (Currently Amended): A method ~~Use according to claim 19 47, characterised in that the~~ wherein said disorder is cancer.

22. (Currently Amended): A method ~~Use according to claim 19 47, wherein said characterised in that the~~ disorder is noncancerous.

23. (Currently Amended): A method ~~Use according to claim 22, wherein said disorder is~~ characterised in that the disorders are selected from the group consisting of psoriasis psoriasis, arthritis, inflammation, endometriosis, scarring, Helicobacter pylori infection, Influenza A, benign ~~benign~~ prostatic hyperplasia, immunological diseases, autoimmune diseases, and immunodeficiency diseases.

24. (Currently Amended): A method Use according to claim 19 ~~47~~, wherein said disorder is characterised in that the disorders are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian ~~cancer~~ cancer, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukemia, ~~leukaemia~~ and acute leukemia ~~leukaemia~~.

25. (Currently Amended): A method Use according to claim 19 ~~47~~, wherein said disorder is characterised in that the disorders are selected from the group consisting of arthritis, restenosis, ~~[[;]]~~ fibrotic disorders, ~~[[;]]~~ mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and neurodegenerative diseases.

26. (Currently Amended): A method Use according to claim 19 ~~47~~, wherein said disorder is characterised in that the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease, and angiogenesis disorders.

27. (Currently Amended): A method Use of a compound according to claim 19 ~~4~~, wherein said compound is as a raf-kinase inhibitor.

28. (Currently Amended): A method Use according to claim 27, wherein characterised in that the raf-kinase is selected from the group consisting of A-Raf, B-Raf and c-Raf1.

29. (Cancelled):


30. (Withdrawn; Currently Amended): A method ~~Method~~ according to claim 29, characterised in that 19, wherein the one or more compounds are administered as a pharmaceutical composition.

31. (Withdrawn; Currently Amended): A method according to claim 19, wherein the disorder ~~Method for the treatment and/or prophylaxis of disorders according to claim 30,~~ characterised in that ~~the disorders~~ is cancerous cell growth mediated by raf kinase.

32. (Cancelled):

33. (Withdrawn; Currently Amended): A method for preparing a compound according to claim 2, said process comprising: ~~Method for producing compounds of formula II, characterised in that~~


a) reacting a compound of formula III



wherein Y, R⁸, p and Ar¹ are as defined in claim 3,

is reacted

b) with a compound of IV,




wherein

LG₁ is a leaving group, preferably a leaving group selected from OR²⁵, wherein R²⁵ is selected from the group consisting of unsubstituted or substituted aromatic residues, unsubstituted or substituted heteroaromatic residues and (O)₂S-R²⁶, wherein R²⁶ is selected from unsubstituted or substituted aromatic residues and unsubstituted or substituted alkyl residues, and wherein E, G, M, Q, U, R⁹, q, X, Ar³, R¹⁰ and r are as defined in claim 3,

and optionally

c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

34. (Currently Amended): A compound according to Compound of formula III,



wherein Y, R⁸, p and Ar¹ are as defined in claim 3.

Ar¹ is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one, two, or three hetero atoms, independently selected from N, O and S,

R⁸ is H, A, OA, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nNR¹¹R¹², (CH₂)_nO(CH₂)_kNR¹¹R¹², (CH₂)_nNR¹¹(CH₂)_kNR¹¹R¹², (CH₂)_nO(CH₂)_kOR¹¹, (CH₂)_nNR¹¹(CH₂)_kOR¹², (CH₂)_nCOOR¹³, (CH₂)_nCOR¹³, (CH₂)_nCONR¹¹R¹², (CH₂)_nNR¹¹COR¹³,

(CH₂)_nNR⁸CONR¹¹R¹², (CH₂)_nNR¹¹SO₂A, (CH₂)_nSO₂NR¹¹R¹²,
 (CH₂)_nS(O)_nR¹³, (CH₂)_nOC(O)R¹³, (CH₂)_nCOR¹³, (CH₂)_nSR¹¹, CH=N-OA,
 CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nCH=N-R¹¹, (CH₂)_nOC(O)NR¹¹R¹²,
 (CH₂)_nNR¹¹COOR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OCF₃,
 (CH₂)_nN(R¹¹)C(R¹³)HCOOR¹², (CH₂)_nN(R¹¹)C(R¹³)HCOR¹¹,
 (CH₂)_nN(R¹¹)CH₂CH₂N(R¹²)CH₂COOR¹¹, (CH₂)_nN(R¹¹)CH₂CH₂NR¹¹R¹²,
 CH=CHCOOR¹³, CH=CHCH₂NR¹¹R¹², CH=CHCH₂NR¹¹R¹²,
 CH=CHCH₂OR¹³, (CH₂)_nN(COOR¹³)COOR¹⁴, (CH₂)_nN(CONH₂)COOR¹³,
 (CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR¹³)COOR¹⁴,
 (CH₂)_nN(CH₂CONH₂)COOR¹³, (CH₂)_nN(CH₂CONH₂)CONH₂,
 (CH₂)_nCHR¹³COR¹⁴, (CH₂)_nCHR¹³COOR¹⁴, (CH₂)_nCHR¹³CH₂OR¹⁴,
 (CH₂)_nOCN and (CH₂)_nNCO,

R¹¹, R¹² are each independently selected from H, A, (CH₂)_mAr³ and (CH₂)_mHet, or in
 NR¹¹R¹², R¹¹ and R¹² form, together with the N-atom they are bound to, a 5-,
 6- or 7- membered heterocyclyl which optionally contains 1 or 2 additional
 hetero atoms, selected from N, O and S,

R¹³, R¹⁴ are each independently selected from H, Hal, A, (CH₂)_mAr⁴ and (CH₂)_mHet,

A is selected from alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy,
 alkoxyalkyl and saturated heterocyclyl,

Ar³, Ar⁴ are each independently from one another aromatic hydrocarbon residues
 comprising 5 to 12 carbon atoms which are optionally substituted by one or
 more substituents, selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵,
 CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶,
 S(O)_nA and OOCR¹⁵,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally
 substituted by one or more substituents, selected from A, Hal, NO₂, CN, OR¹⁵,

LG₁ is a leaving group, ~~preferably a leaving group~~ selected from OR²⁵, wherein

R²⁵ is selected from ~~the group consisting of~~ unsubstituted or substituted aromatic residues, unsubstituted or substituted heteroaromatic residues and (O)₂S-R²⁶, wherein

R²⁶ is selected from unsubstituted or substituted aromatic residues and unsubstituted or substituted alkyl residues, and wherein E, G, M, Q, U, R⁹, q, X, R³, R¹⁰ and r are as defined in claim 3.

Ar² is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one, two, or three hetero atoms, independently selected from N, O and S.

E, G, M, Q and U are each independently selected from carbon atoms and nitrogen atoms, with the proviso that one or more of E, G, M, Q and U are carbon atoms and that X is bonded to a carbon atom.

R⁹ and R¹⁰ are each independently selected from H, A, OA, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nNR¹¹R¹², (CH₂)_nO(CH₂)_kNR¹¹R¹², (CH₂)_nNR¹¹(CH₂)_kNR¹¹R¹², (CH₂)_nO(CH₂)_kOR¹¹, (CH₂)_nNR¹¹(CH₂)_kOR¹², (CH₂)_nCOOR¹³, (CH₂)_nCOR¹³, (CH₂)_nCONR¹¹R¹², (CH₂)_nNR¹¹COR¹³, (CH₂)_nR⁸CONR¹¹R¹², (CH₂)_nNR¹¹SO₂A, (CH₂)_nSO₂NR¹¹R¹², (CH₂)_nS(O)_nR¹³, (CH₂)_nOC(O)R¹³, (CH₂)_nCOR¹³, (CH₂)_nSR¹¹, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nCH=N-R¹¹, (CH₂)_nOC(O)NR¹¹R¹², (CH₂)_nNR¹¹COOR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OCF₃, (CH₂)_nN(R¹¹)C(R¹³)HCOOR¹², (CH₂)_nN(R¹¹)C(R¹³)HCOOR¹¹, (CH₂)_nN(R¹¹)CH₂CH₂N(R¹²)CH₂COOR¹¹, (CH₂)_nN(R¹¹)CH₂CH₂NR¹¹R¹², CH=CHCOOR¹³, CH=CHCH₂NR¹¹R¹², CH=CHCH₂NR¹¹R¹², CH=CHCH₂OR¹³, (CH₂)_nN(COOR¹³)COOR¹⁴, (CH₂)_nN(CONH₂)/COOR¹³, (CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR¹³)COOR¹⁴,

$(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$,
 $(\text{CH}_2)_n\text{OCN}$ and $(\text{CH}_2)_n\text{NCO}$.

R^{11} , R^{12} are each independently selected from H, A, $(\text{CH}_2)_m\text{Ar}^3$ and $(\text{CH}_2)_m\text{Het}$, or in
 $\text{NR}^{11}\text{R}^{12}$, R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-,
6- or 7- membered heterocyclcyl which optionally contains 1 or 2 additional
hetero atoms, selected from N, O and S,

R^{13} , R^{14} are each independently selected from H, Hal, A, $(\text{CH}_2)_m\text{Ar}^4$ and $(\text{CH}_2)_m\text{Het}$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylencycloalkyl, alkoxy,
alkoxyalkyl and saturated heterocyclcyl,

Ar^3 , Ar^4 are each independently from one another aromatic hydrocarbon residues
comprising 5 to 12 carbon atoms which are optionally substituted by one or
more substituents, selected from A, Hal, NO_2 , CN, OR^{15} , $\text{NR}^{15}\text{R}^{16}$, COOR^{15} ,
 $\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$, COR^{15} , $\text{SO}_2\text{R}^{15}\text{R}^{16}$,
 $\text{S(O)}_n\text{A}$ and OOCR^{15} ,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally
substituted by one or more substituents, selected from A, Hal, NO_2 , CN, OR^{15} ,
 $\text{NR}^{15}\text{R}^{16}$, COOR^{15} , $\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$,
 COR^{15} , $\text{SO}_2\text{R}^{15}\text{R}^{16}$, $\text{S(O)}_n\text{A}$ and OOCR^{15} ,

R^{15} , R^{16} are independently selected from H, A, and $(\text{CH}_2)_m\text{Ar}^6$,

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by
one or more substituents selected from methyl, ethyl, propyl, 2-propyl, tert.-
butyl, Hal, CN, OH, NH_2 and CF_3 ,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h-O-(CHR^{12})_i$,

Q is selected from T, $CH^{15}H^{16}$, $(CHal_2)_j$, $(O-CHR^{18})_j$, $(CHR^{18}-O)_j$, $CR^{18}=CR^{19}$, $(O-CHR^{18}CHR^{19})_j$, $CHR^{18}CHR^{19}-O)_j$, C=O, C=S, C=NR¹⁵, CH(OR¹⁵), C(OR¹⁵)(OR²⁰), C(=O)O, OC(=O), OC(=O)O, C(=N(R¹⁵), N(R¹⁵)C(=O), OC(=O)N(R¹⁵), N(R¹⁵)C(=O)O, CH=N-O, CH=N-NR¹⁵, OC(O)NR¹⁵, NR¹⁵C(O)O, S=O, SO₂, SO₂NR¹⁵ and NR¹⁵SO₂,

T is selected from O, S, N-R¹⁵,

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6,

j is 1, 2, 3, 4, 5 or 6,

Y is selected from O/S, NR²¹, C(R²²)-NO₂, C(R²²)-CN and C(CN)₂,

O/S is O or S,

R²¹ is independently selected from H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,


R²² is independently selected from H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$,

q is 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3, and

Hal is independently selected from F, Cl, Br and I.

36. (New): A compound according to claim 3, wherein said compound is of the Formula II':



37. (New): A compound according to claim 3, wherein

Ar¹ is phenyl, pyridinyl, pyrimidyl, chinolinyl, isochinolinyl, thiophenyl, thiadiazolyl, indolyl, benzothiadiazolyl, benzotriazolyl, benzodioxolyl, oxazolyl, isoxazolyl, pyrazolyl or imidazolyl,

Ar² is phenyl, pyridinyl, pyrrazolyl, pyrimidyl, chinolinyl, isochinolinyl, thiophenyl, thiadiazolyl, benzothiadiazolyl, oxazolyl, isoxazolyl, pyrazolyl and imidazolyl, and

Ar³ to Ar⁶ are each, independently from one another, phenyl, naphthyl or biphenyl, which in each case is unsubstituted or substituted by one or more substituents, selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_wA and OOCR¹⁵.

38. (New): A compound according to claim 3, wherein Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)-piperazyl, 4-methylpiperazin-1-yl amine, 4-morpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)-pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)-imidazolidinyl, thiophen-2-yl, thiophen-3-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, chinolinyl, isochinolinyl, 2-pyridazyl, 4-pyridazyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 2-pyrazinyl, or 3-pyrazinyl, which in each case is unsubstituted or substituted by A, CN and Hal.

39. (New): A compound according to claim 3, wherein

E, G, M, Q, U are carbon atoms,

R⁹ is H,

Ar² is phenyl, pyridinyl or pyrrolyl,

R¹⁰ is H or CONCH₃,

r is 1, and

X is O or a bond.

40. (New): A compound according to claim 3, wherein

Ar¹ is phenyl,

R⁸ is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

p is 1 or 2,

E, G, M, Q, U are carbon atoms,

R⁹ is H,

Ar² is phenyl, pyridinyl or pyrrolyl,

R¹⁰ is H or CONCH₃,

r is 1, and

X is O or a bond.

41. (New): A compound according to claim 3, wherein

Ar¹ is phenyl,

R⁸ is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

p is 1 or 2,

E, G, M, Q, U are carbon atoms,

R⁹ is H,

Ar² is phenyl, pyridinyl or pyrrolyl,

R¹⁰ is H or CONCH₃,

r is 1, and

X is O.

42. (New): A compound according to claim 3, wherein

Ar¹ is phenyl,

R⁸ is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, tert.-butyl, methoxy,

ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert.-butoxy, Hal, CHal₃ or OCHal₃,

p is 1 or 2,

E, G, M, Q, U are carbon atoms,

R⁹ is H,

Ar² is phenyl or pyridinyl,

R¹⁰ is H or CONCH₃, where when Ar² is pyridinyl, R¹⁰ is bonded in a vicinal position to the nitrogen atom of the pyridinyl residue,

r is 1, and

X is O.

43. (New): A compound according to claim 39, wherein Y is O.

44. (New): A compound according to claim 40, wherein Y is O.

45. (New): A compound according to claim 41, wherein Y is O.

46. (New): A compound according to claim 42, wherein Y is O.

47. (New): A compound according to claim 3, wherein (R⁸)_p-Ar¹ is 3-acetyl-phenyl, 4-acetyl-phenyl, 2-bromo-phenyl, 3-bromo-phenyl, 4-bromo-phenyl, 4-bromo-2-chloro-phenyl, 4-bromo-3-methyl-phenyl, 4-bromo-3-trifluoromethyl-phenyl, 2-chloro-phenyl, 2-chloro-4-trifluoromethyl-phenyl, 2-chloro-5-trifluoromethyl-phenyl, 3-chloro-phenyl, 3-chloro-4-methyl-phenyl, 3-chloro-4-methoxy-phenyl, 3-chloro-4-methoxy-phenyl, 4-chloro-phenyl, 4-chloro-2-trifluoromethyl-phenyl, 4-chloro-3-trifluoromethyl-phenyl, 4-chloro-2-methyl-phenyl, 5-chloro-2-methyl-phenyl, 5-chloro-2-methoxy-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-phenyl, 2,5-dichloro-phenyl, 3,4-dichloro-phenyl, 3,5-dichloro-phenyl, 2,4,5-trichloro-phenyl, 4-fluoro-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 4-ethoxy-phenyl, 2-methoxy-phenyl, 2-methoxy-5-trifluoromethyl-phenyl, 4-methoxy-phenyl, 2,5-dimethoxy-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 3-trifluoromethoxy-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 3,5-bis-trifluoromethyl-phenyl, 3-methoxy-phenyl, 3-methylsulfanyl-phenyl, 4-methylsulfanyl-phenyl, o-tolyl (2-methyl-phenyl), m-tolyl (3-methyl-phenyl), p-tolyl (4-methyl-phenyl), 2,3-dimethyl-phenyl, 2,3-di-

methyl-phenyl, 2,5-dimethyl-phenyl, 3,4-dimethyl-phenyl, 3,5-dimethyl-phenyl, 2-ethyl-phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 4-isopropyl-phenyl, 4-n-butyl-phenyl, 4-tert-butyl-phenyl, 4-n-butoxy-phenyl, or 4-tert.-butoxy-phenyl.